NICM
BIO icon

Neo Ivy Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Neo Ivy Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,626
Closed -$878K – 278
2024
Q3 		$878K Buy
+2,626
New +$834K 0.28% 140

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Neo Ivy Capital Management's BIO Position: Q4 2024 in Review

Neo Ivy Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 2,626 shares — an estimated $878K sold.

Neo Ivy Capital Management first reported a position in BIO in Q3 2024 and held it in 1 quarter. The position peaked at $878K in Q3 2024. 456 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

  • Neo Ivy Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
  • Neo Ivy Capital Management sold 2,626 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $878K.
  • Neo Ivy Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2024 and held it in 1 quarter.
  • Neo Ivy Capital Management's Bio-Rad Laboratories Class A position peaked at $878K in Q3 2024.
  • 456 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Neo Ivy Capital Management's 13F filing for Q4 2024, filed 18 Feb 2025.